Cardiology
Merck KGaA’s Saturnus Bio bet signals a shift to genotype-driven cardiology, and a looming readiness gap for health systems
Merck KGaA’s $50 million build-to-buy collaboration with Versant Ventures to launch Saturnus Bio signals growing industry interest in rare genetic cardiomyopathies. The science is moving toward targeted gene modulation and genotype-defined treatment. The policy challenge is whether health systems can build the genetic testing, counselling, family screening and reimbursement pathways needed to make precision cardiology…
A new Lp(a) threshold could reshape cardiovascular risk assessment
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
Africa’s Cardiovascular Decade Is a System-Design Problem
Inherited Lipid Screening Becomes Europe’s Prevention Test
ATTR Gene Editing Restarts, But Safety Becomes the Access Question
Routine CT Scans Could Become a Heart Failure Early-Warning System
Risk Prediction Cannot Simply Be Imported From Europe
Personalised Cardiology Needs a Digital Fabric, Not Just More Data
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.